Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium

Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the ...

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, tells us about the results of the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, discusses the safety profile of bemarituzumab from the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial as presented at the 2021 Gastrointestinal Cancers Symposium

Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial ...

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, considers whether ctDNA testing informs targeted therapy choices for patients with gastric cancer

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer and whether potential improvements in outcomes are on the horizon for this disease

Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer ...

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, tells us about the NuTide:121 trial as presented at the 2021 Gastrointestinal Cancers Symposium

Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, tells us ...